# TAAR1

## Overview
TAAR1 (trace amine-associated receptor 1) is a gene that encodes a G protein-coupled receptor (GPCR) belonging to the class A GPCR family. The receptor, also known as trace amine-associated receptor 1, is characterized by its seven transmembrane alpha-helices, a hallmark of GPCRs, and plays a crucial role in modulating neurotransmitter systems, particularly those involving dopamine and serotonin (Glyakina2021Search; Berry2017Pharmacology). TAAR1 is expressed in various tissues, including the brain and pancreatic β-cells, indicating its involvement in both central and peripheral physiological processes (Berry2017Pharmacology). The receptor's interactions with other proteins, such as dopamine D2 receptors and the dopamine transporter, underscore its significance in regulating dopaminergic signaling pathways and maintaining neurotransmitter homeostasis (Grandy2007Trace; Berry2017Pharmacology). Clinically, TAAR1 has been implicated in neuropsychiatric and metabolic disorders, with genetic variants affecting receptor function and contributing to conditions such as schizophrenia, bipolar disorder, and diabetes (Mühlhaus2017Investigation; Rutigliano2019NonFunctional).

## Structure
TAAR1 (trace amine-associated receptor 1) is a G protein-coupled receptor (GPCR) that is part of the class A GPCR family. It is characterized by the presence of seven transmembrane alpha-helices, a common feature of GPCRs (Glyakina2021Search). The primary structure of TAAR1 includes key amino acid residues such as Asp68, Asp102, and Asp284, which are crucial for ligand binding and receptor activation (Glyakina2021Search). These aspartic acid residues are involved in forming hydrogen bonds with ligands, playing a significant role in the receptor's function (Glyakina2021Search).

The secondary and tertiary structures of TAAR1 have been modeled using computational tools like GPCR-I-TASSER, which predict the spatial arrangement of the receptor based on known structures of related proteins (Glyakina2021Search). The receptor's structure is stabilized by disulfide bridges formed by conserved cysteine residues, which are important for maintaining the receptor's integrity (Glyakina2021Search).

TAAR1 may undergo post-translational modifications such as phosphorylation and glycosylation, which can influence its signaling and functional properties. These modifications are typical for GPCRs and contribute to the receptor's regulatory mechanisms (Glyakina2021Search). The receptor's ability to dimerize, potentially through disulfide bridges, suggests a quaternary structure that may be important for its stability and function (Glyakina2021Search).

## Function
TAAR1 (trace amine-associated receptor 1) is a G protein-coupled receptor that plays a significant role in modulating neurotransmitter systems, particularly dopamine and serotonin, in healthy human cells. It is primarily coupled to the Gs-protein, which stimulates the production of cyclic adenosine monophosphate (cAMP) and recruits the β-arrestin 2 cascade, a form of biased agonism (Berry2017Pharmacology). TAAR1 is involved in regulating dopaminergic systems by preventing dopaminergic hyperactivity through interaction with D2-like dopamine receptors, which involves TAAR1-D2 heterodimerization (Berry2017Pharmacology). This receptor also influences serotonergic neurotransmission and enhances glutamatergic transmission by regulating NMDA receptor sub-units, which is relevant for preventing dopaminergic hyperactivity and overcoming glutamatergic hypoactivity (Berry2017Pharmacology).

TAAR1 is expressed in various tissues, including the brain, pancreatic β-cells, and leukocytes, suggesting its involvement in both central and peripheral physiological processes (Berry2017Pharmacology). In the brain, TAAR1 modulates reward circuits, cognitive processes, and mood states, while in the pancreas, it may play a role in energy metabolism (Berry2017Pharmacology). TAAR1's function as an endogenous rheostat helps modulate receptor activation efficacy in neurotransmitter systems, contributing to the maintenance of homeostasis in dopaminergic activity (Berry2017Pharmacology).

## Clinical Significance
Mutations and alterations in the TAAR1 gene have been implicated in various neuropsychiatric and metabolic disorders. Genetic studies have identified several single nucleotide variants (SNVs) in the TAAR1 gene, with some variants showing defective receptor function in vitro. Notably, the missense variants R23C, Y131C, and C263R are associated with decreased cell surface expression and impaired receptor function, potentially contributing to mental disorders such as schizoaffective disorder and bipolar disorder (Rutigliano2019NonFunctional).

TAAR1 is involved in the regulation of dopamine and serotonin neurotransmission, which are critical in the etiology of neuropsychiatric disorders. Dysregulation of these pathways has been linked to conditions such as schizophrenia, ADHD, bipolar disorder, and major depression (Schwartz2018Trace). TAAR1 agonists have shown potential therapeutic effects, including antipsychotic and antidepressant properties, and may reduce stimulant-induced reward and relapse to drug-seeking behavior (Schwartz2018Trace).

In metabolic disorders, TAAR1 variants like R23C and S49L have been associated with impaired insulin secretion and glucose homeostasis, suggesting a role in obesity and diabetes (Mühlhaus2017Investigation). These findings highlight the clinical significance of TAAR1 in both mental and metabolic health.

## Interactions
TAAR1 interacts with various proteins and is involved in multiple signaling pathways. It forms a complex with the Gs protein, which is crucial for its activation and subsequent intracellular signaling. The C-terminal helix of the Gα subunit extends into the receptor's transducer binding site, interacting with the cytoplasmic ends of transmembrane helices 2, 3, 5, 6, and 7 of TAAR1 (Zilberg2024Molecular). TAAR1 also interacts with dopamine D2 receptors through heterodimerization, which influences dopaminergic signaling pathways. This interaction promotes signaling via the β-arrestin 2 pathway, a form of biased agonism, and is significant in regulating dopaminergic systems (Berry2017Pharmacology).

TAAR1 is known to modulate neurotransmitter systems by interacting with transporters such as the dopamine transporter (DAT). Co-expression of TAAR1 with DAT enhances cAMP production in response to certain agonists, suggesting a functional interaction between these proteins (Grandy2007Trace). Additionally, TAAR1 can heterodimerize with TAAR2, which is important for the chemotactic response of neutrophils to 2-phenylethylamine, indicating a role in immune response modulation (Berry2017Pharmacology). These interactions highlight TAAR1's role in modulating neurotransmitter release and reuptake, impacting various physiological processes.


## References


[1. (Berry2017Pharmacology) Mark D. Berry, Raul R. Gainetdinov, Marius C. Hoener, and Mohammed Shahid. Pharmacology of human trace amine-associated receptors: therapeutic opportunities and challenges. Pharmacology &amp; Therapeutics, 180:161–180, December 2017. URL: http://dx.doi.org/10.1016/j.pharmthera.2017.07.002, doi:10.1016/j.pharmthera.2017.07.002. This article has 165 citations.](https://doi.org/10.1016/j.pharmthera.2017.07.002)

[2. (Glyakina2021Search) Anna V. Glyakina, Constantine D. Pavlov, Julia V. Sopova, Raul R. Gainetdinov, Elena I. Leonova, and Oxana V. Galzitskaya. Search for structural basis of interactions of biogenic amines with human taar1 and taar6 receptors. International Journal of Molecular Sciences, 23(1):209, December 2021. URL: http://dx.doi.org/10.3390/ijms23010209, doi:10.3390/ijms23010209. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms23010209)

[3. (Zilberg2024Molecular) Gregory Zilberg, Alexandra K. Parpounas, Audrey L. Warren, Shifan Yang, and Daniel Wacker. Molecular basis of human trace amine-associated receptor 1 activation. Nature Communications, January 2024. URL: http://dx.doi.org/10.1038/s41467-023-44601-4, doi:10.1038/s41467-023-44601-4. This article has 8 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-023-44601-4)

[4. (Rutigliano2019NonFunctional) Grazia Rutigliano, Julia Bräunig, Claudia Del Grande, Vittoria Carnicelli, Isabella Masci, Sergio Merlino, Gunnar Kleinau, Luca Tessieri, Simone Pardossi, Sarah Paisdzior, Liliana Dell’Osso, Heike Biebermann, and Riccardo Zucchi. Non-functional trace amine-associated receptor 1 variants in patients with mental disorders. Frontiers in Pharmacology, September 2019. URL: http://dx.doi.org/10.3389/fphar.2019.01027, doi:10.3389/fphar.2019.01027. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fphar.2019.01027)

[5. (Schwartz2018Trace) Michael D. Schwartz, Juan J. Canales, Riccardo Zucchi, Stefano Espinoza, Ilya Sukhanov, and Raul R. Gainetdinov. Trace amine-associated receptor 1: a multimodal therapeutic target for neuropsychiatric diseases. Expert Opinion on Therapeutic Targets, 22(6):513–526, June 2018. URL: http://dx.doi.org/10.1080/14728222.2018.1480723, doi:10.1080/14728222.2018.1480723. This article has 50 citations and is from a peer-reviewed journal.](https://doi.org/10.1080/14728222.2018.1480723)

[6. (Mühlhaus2017Investigation) Jessica Mühlhaus, Juliane Dinter, Sabine Jyrch, Alexander Teumer, Simon F. Jacobi, Georg Homuth, Peter Kühnen, Susanna Wiegand, Annette Grüters, Henry Völzke, Klemens Raile, Gunnar Kleinau, Heiko Krude, and Heike Biebermann. Investigation of naturally occurring single-nucleotide variants in human taar1. Frontiers in Pharmacology, November 2017. URL: http://dx.doi.org/10.3389/fphar.2017.00807, doi:10.3389/fphar.2017.00807. This article has 19 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fphar.2017.00807)

[7. (Grandy2007Trace) David K. Grandy. Trace amine-associated receptor 1—family archetype or iconoclast? Pharmacology &amp; Therapeutics, 116(3):355–390, December 2007. URL: http://dx.doi.org/10.1016/j.pharmthera.2007.06.007, doi:10.1016/j.pharmthera.2007.06.007. This article has 155 citations.](https://doi.org/10.1016/j.pharmthera.2007.06.007)